Join our daily newsletter At The Bell to receive exclusive market insights
- Prescient Therapeutics (PTX) signs a deal with Thermo Fisher Scientific to accelerate the development of its OmniCar platform
- The work program will aim to develop the next generation OmniCAR cells that can be produced with greater efficiency, lower costs, and unmatched reproducibility
- PTX says it’s optimistic this agreement will accelerate the development of OmniCAR to the point its internal OmniCAR programs can include the advancements this agreement produces
- Prescient Therapeutics is up 2.86 per cent, trading at 18 cents at 12:01 pm AEST
Prescient Therapeutics (PTX) has signed a deal with Thermo Fisher Scientific to accelerate the development of its OmniCar platform.
Under the agreement, a development will be constructed to evaluate the potential of using automated, closed cell therapy solutions to develop a novel process of manufacturing cell therapies on the OmniCAR platform using non-viral methods.
The work program will develop the next generation OmniCAR cells that can be produced with greater efficiency, lower costs, and unmatched reproducibility.
Prescient’s focus will remain on creating OmniCAR cells with Thermo Fisher’s portfolio of proprietary equipment, and specialised cell and gene therapy manufacturing expertise.
Prescient Managing Director and CEO Steven Yatomi-Clarke said the company is delighted to enter this agreement with Thermo Fisher to accelerate the development of its OmniCAR platform.
“Whilst Prescient elected to develop its first internal OmniCAR programs using the validated approach of lentiviral transduction, we always have an eye on the future for any emerging advantages that can be incorporated into our programs whilst mitigating development risk,” Mr Yatomi-Clarke said.
“We are optimistic that this agreement with Thermo Fisher will accelerate the development of the OmniCAR platform to the point where one or more of Prescient’s internal OmniCAR programs can incorporate the advancements this agreement produces.
“Importantly, the agreement should result in an improved product and process that can be decentralised and therefore scaled with high efficiency and reproducibility.”
Prescient Therapeutics was up 2.86 per cent, trading at 18 cents at 12:01 pm AEST.
